Lexeo Therapeutics Inc. Common Stock
LXEO | NASDAQ
$4.11
+$0.03 (+0.74%)
Sep 22, 2026, 1:29 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 654K | 1.66M | 518.48K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | 654K | 1.66M | 518.48K |
Operating Income | -109.26M | -105.77M | -68.51M | -60.51M | -50.64M | -4.59M |
Interest Income | 6.13M | 7.56M | 2.87M | 1.33M | 15K | n/a |
Pretax Income | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M | -5.15M |
Net Income | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M | -5.15M |
Selling & General & Admin | 45.46M | 31.68M | 15.38M | 12M | 7.17M | 787.5K |
Research & Development | 63.8M | 74.09M | 53.13M | 49.16M | 45.12M | 4.32M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 109.26M | 105.77M | 68.51M | 61.16M | 52.29M | 5.11M |
Interest Expense | 206K | 114K | 205K | 91K | n/a | 147.15K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 109.26M | 105.77M | 68.51M | 61.16M | 52.29M | 5.11M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 53.65M | 31.79M | 26.65M | 25.17M | 25.17M | 25.17M |
Shares Outstanding (Diluted) | 53.65M | 31.79M | 26.65M | 25.17M | 25.17M | 25.17M |
EPS (Basic) | -1.86 | -3.09 | -2.49 | -2.36 | -2.01 | -0.20 |
EPS (Diluted) | -1.86 | -3.09 | -2.49 | -2.40 | -2.01 | -0.20 |
EBITDA | -97.68M | -96.19M | -64.35M | -58.04M | -50.61M | -4.59M |
EBIT | -99.76M | -98.2M | -66.19M | -59.19M | -50.62M | -4.59M |
Depreciation & Amortization | 2.08M | 2M | 1.84M | 1.15M | 13K | n/a |
Add to Watchlist
Select watchlists to add or remove LXEO